Progress in understanding the structure-activity relationships of P-glycoprotein

被引:156
作者
Stouch, TR
Gudmundsson, A
机构
[1] Bristol Myers Squibb Co, Princeton, NJ 08543 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
关键词
P-glycoprotein; P-gp; SAR; structure-activity relationships; molecular modeling; MDR; multiple drug resistance;
D O I
10.1016/S0169-409X(02)00006-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Efflux out of cells by P-glycoprotein (P-gp) represents a serious liability for pharmaceuticals, particularly for anti-cancer drugs. Consequently, identification of compounds as potential substrates is important for understanding their bioavailability. Also, the development of agents which reverse this multi-drug resistance phenotype has received considerable attention. Assays for determining these activities axe reviewed. Recent literature and studies into the structure-activity relationships (SAR) of the resulting data are discussed. Multiple binding sites and other complicating factors have prevented the development of a truly general, conclusive SAR either for substrate or inhibitory activities. Consequently, many models have tended to address only very general properties, such as lipophilicity and size. However, progress has been made in the last few years toward more specific SAR suggesting well-defined structural features responsible for both activities. The future of understanding the details of P-gp SAR lies in more specific assays that target specific binding sites and mechanisms of action. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:315 / 328
页数:14
相关论文
共 72 条
  • [1] Biochemical, cellular, and pharmacological aspects of the multidrug transporter
    Ambudkar, SV
    Dey, S
    Hrycyna, CA
    Ramachandra, M
    Pastan, I
    Gottesman, MM
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 : 361 - 398
  • [2] PARTIAL-PURIFICATION AND RECONSTITUTION OF THE HUMAN MULTIDRUG-RESISTANCE PUMP - CHARACTERIZATION OF THE DRUG-STIMULATABLE ATP HYDROLYSIS
    AMBUDKAR, SV
    LELONG, IH
    ZHANG, JP
    CARDARELLI, CO
    GOTTESMAN, MM
    PASTAN, I
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (18) : 8472 - 8476
  • [3] P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs
    Aungst, BJ
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1999, 39 (1-3) : 105 - 116
  • [4] Bain LJ, 1997, ENVIRON HEALTH PERSP, V105, P812, DOI 10.2307/3433698
  • [5] Bain LJ, 1996, TOXICOL APPL PHARM, V141, P288, DOI 10.1016/S0041-008X(96)80035-4
  • [6] Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells
    Barnes, KM
    Dickstein, B
    Cutler, GB
    Fojo, T
    Bates, SE
    [J]. BIOCHEMISTRY, 1996, 35 (15) : 4820 - 4827
  • [7] PHOTOAFFINITY SUBSTRATES FOR P-GLYCOPROTEIN
    BECK, WT
    QIAN, XD
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 43 (01) : 89 - 93
  • [8] Novel multidrug resistance reversal agents
    Berger, D
    Citarella, R
    Dutia, M
    Greenberger, L
    Hallett, W
    Paul, R
    Powell, D
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (12) : 2145 - 2161
  • [9] BHAT UG, 1995, MOL PHARMACOL, V48, P682
  • [10] EXPRESSION OF AN MDR GENE IS ASSOCIATED WITH A NEW FORM OF RESISTANCE TO DEXAMETHASONE-INDUCED APOPTOSIS
    BOURGEOIS, S
    GRUOL, DJ
    NEWBY, RF
    RAJAH, FM
    [J]. MOLECULAR ENDOCRINOLOGY, 1993, 7 (07) : 840 - 851